Synthesis and evaluation of novel 3,4,6-substituted 2-quinolones as FMS kinase inhibitors
摘要:
A series of 3,4,6-substituted 2-quinolones has been synthesized and evaluated as inhibitors of the kinase domain of macrophage colony-stimulating factor-1 receptor (FMS). The fully optimized compound, 4-(4-ethyl-phenyl)-3-(2-methyl-3H-imidazol-4yl)-2-quinolone-6-carbonitrile 21b, has an IC50 of 2.5 nM in an in vitro assay and 5.0 nM in a bone marrow-derived macrophage cellular assay. Inhibition of FMS signaling in vivo was also demonstrated in a mouse pharmacodynamic model. (c) 2008 Elsevier Ltd. All rights reserved.
Quinolinone derivatives as inhibitors of c-fms kinase
申请人:Wall J. Mark
公开号:US20050049274A1
公开(公告)日:2005-03-03
The invention is directed to compounds of Formulae I and II:
wherein R
1
, R
2
, R
3
, R
5
, R
6
, Y
1
, Y
2
, Y
3
, Y
4
and X are set forth in the specification, as well as solvates, hydrates, tautomers or pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase.
QUINOLINONE DERIVATIVES AS INHIBITORS OF C-FMS KINASE
申请人:JANSSEN PHARMACEUTICA N.V.
公开号:EP1660087A2
公开(公告)日:2006-05-31
US7326788B2
申请人:——
公开号:US7326788B2
公开(公告)日:2008-02-05
[EN] QUINOLINONE DERIVATIVES AS INHIBITORS OF C-FMS KINASE<br/>[FR] DERIVES DE QUINOLINONE EN TANT QU'INHIBITEURS DE C-FMS KINASE
申请人:JANSSEN PHARMACEUTICA NV
公开号:WO2005009967A3
公开(公告)日:2005-03-24
Synthesis and evaluation of novel 3,4,6-substituted 2-quinolones as FMS kinase inhibitors
作者:Mark J. Wall、Jinsheng Chen、Sanath Meegalla、Shelley K. Ballentine、Kenneth J. Wilson、Renee L. DesJarlais、Carsten Schubert、Margery A. Chaikin、Carl Crysler、Ioanna P. Petrounia、Robert R. Donatelli、Edward J. Yurkow、Lisa Boczon、Marie Mazzulla、Mark R. Player、Raymond J. Patch、Carl L. Manthey、Christopher Molloy、Bruce Tomczuk、Carl R. Illig
DOI:10.1016/j.bmcl.2008.01.088
日期:2008.3
A series of 3,4,6-substituted 2-quinolones has been synthesized and evaluated as inhibitors of the kinase domain of macrophage colony-stimulating factor-1 receptor (FMS). The fully optimized compound, 4-(4-ethyl-phenyl)-3-(2-methyl-3H-imidazol-4yl)-2-quinolone-6-carbonitrile 21b, has an IC50 of 2.5 nM in an in vitro assay and 5.0 nM in a bone marrow-derived macrophage cellular assay. Inhibition of FMS signaling in vivo was also demonstrated in a mouse pharmacodynamic model. (c) 2008 Elsevier Ltd. All rights reserved.